INSULET CORP

Insulet Corporation reported strong financial results for the second quarter and first six months of 2026. Revenue for Q2 2026 increased by 23.5% to $801.7 million, with net income soaring by 322.2% to $95.0 million and diluted EPS reaching $1.37. The company also announced an extension of its share repurchase program and the approval of an additional $350 million for repurchases, following the completion of $300 million in accelerated share repurchases earlier in the year. A significant legal development saw the Federal Circuit reverse a prior trade secret judgment against EOFlow, which had no impact on Insulet's consolidated financial statements as damages were not previously accrued.

Insulet Corporation reported strong second-quarter 2026 financial results, with revenue reaching $801.7 million, a 23.5% increase, surpassing its guidance. Adjusted diluted earnings per share rose significantly to $1.66, up 41.5% year-over-year. The company also expanded its global footprint by launching Omnipod 5 in Spain and enhanced its ecosystem with broader sensor compatibility. While Insulet updated its full-year 2026 revenue guidance slightly lower to 20%-22% growth, it raised its adjusted EPS growth outlook to over 30%.

Insulet Corporation announced the appointment of Jonathan J. Mazelsky as a Class II director to its Board of Directors, effective July 1, 2026. Mr. Mazelsky brings extensive experience, having served as Executive Chair and former President and CEO of IDEXX Laboratories, Inc., and holding various leadership roles at Philips Healthcare and Agilent Technologies. As a non-employee director, he will receive an initial grant of restricted stock units valued at $216,548 and cash compensation.

Insulet Corporation announced a voluntary Medical Device Correction for specific lots of Omnipod® products due to a manufacturing issue causing cannula tears and potential insulin under-delivery. This action, separate from a prior correction, affects approximately 7 million Pods, with 60% already consumed or expired. The company expects to incur up to $50 million in costs in 2026, which will be excluded from adjusted results, but does not anticipate disruption to customer shipments or changes to its 2026 guidance or long-term growth profile.

Insulet Corp reported strong first-quarter 2026 results with total revenue increasing by 33.9% to $761.7 million and diluted EPS rising by 160% to $1.30. The company expanded its share repurchase program by an additional $350 million and repurchased $300 million of common stock. Insulet also launched Omnipod 5 in five Middle East countries and advanced development of its next-generation AID product, Omnipod 6, including enrolling the first participant in the EVOLVE pivotal study for type 2 diabetes.

Insulet Corporation reported strong first-quarter 2026 financial results, with revenue reaching $761.7 million, a 33.9% increase year-over-year, exceeding its guidance range. Net income significantly improved to $91.1 million, or $1.30 per diluted share. Following this performance, the company raised its full-year 2026 total company revenue guidance to 21-23% constant currency growth and highlighted strategic advancements including the expansion of Omnipod 5 availability and a share repurchase program.